Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Diagnosis, management and prevention of Candida auris in hospitals: Position statement of the Australasian Society for Infectious Diseases.

Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, Marshall CL, Morris AJ, Morrissey CO, Roy R, Slavin MA, Stewardson AJ, Worth LJ, Heath CH; Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Hospital Infection Special Interest Group (HICSIG); both of the Australasian Society for Infectious Diseases (ASID).

Intern Med J. 2019 Aug 19. doi: 10.1111/imj.14612. [Epub ahead of print]

PMID:
31424595
2.

Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living with HIV: a narrative review.

Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJ, Gervasoni C.

Ther Drug Monit. 2019 Aug 5. doi: 10.1097/FTD.0000000000000684. [Epub ahead of print]

PMID:
31393332
3.

Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study.

Keighley C, Chen SC, Marriott D, Pope A, Chapman B, Kennedy K, Bak N, Underwood N, Wilson HL, McDonald K, Darvall J, Halliday C, Kidd S, Nguyen Q, Hajkowicz K, Sorrell TC, Van Hal S, Slavin MA.

BMC Infect Dis. 2019 May 21;19(1):445. doi: 10.1186/s12879-019-4065-5.

4.

Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.

Gould M, Ginn AN, Marriott D, Norris R, Sandaradura I.

Int J Antimicrob Agents. 2019 Aug;54(2):240-244. doi: 10.1016/j.ijantimicag.2019.05.013. Epub 2019 May 17.

PMID:
31108222
5.

Evaluation of the EasyScreen Protozoan Detection Kit for the diagnosis of Entamoeba histolytica.

Cao M, Ellis JT, Marriott D, Harkness J, Stark D.

Pathology. 2019 Jun;51(4):426-428. doi: 10.1016/j.pathol.2019.01.012. Epub 2019 May 7. No abstract available.

PMID:
31072643
6.

Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.

Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, Carland JE, Stocker SL, Wicha SG.

Clin Microbiol Infect. 2019 Mar 11. pii: S1198-743X(19)30097-7. doi: 10.1016/j.cmi.2019.02.029. [Epub ahead of print]

PMID:
30872102
7.

Whole Genome Sequencing of Australian Candida glabrata Isolates Reveals Genetic Diversity and Novel Sequence Types.

Biswas C, Marcelino VR, Van Hal S, Halliday C, Martinez E, Wang Q, Kidd S, Kennedy K, Marriott D, Morrissey CO, Arthur I, Weeks K, Slavin MA, Sorrell TC, Sintchenko V, Meyer W, Chen SC.

Front Microbiol. 2018 Dec 3;9:2946. doi: 10.3389/fmicb.2018.02946. eCollection 2018.

8.

Cluster of invasive Mycobacteria chimaera infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacement.

Overton K, Mennon V, Mothobi N, Neild B, Martinez E, Masters J, Grant P, Akhunji Z, Su WY, Torda A, Whyte CM, Lloyd A, Weatherall C, Hofmeyr A, Foo H, Brookes K, Marriott D, Sintchenko V, Clezy K, Konecny P, Post JJ.

Intern Med J. 2018 Dec;48(12):1514-1520. doi: 10.1111/imj.14093.

PMID:
30517986
9.

Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens.

Milliken E, de Zwart AES, Alffenaar JC, Marriott DJE, Riezebos-Brilman A, Schteinman A, Evans AM, Glanville AR, Verschuuren EAM, Reuter SE.

J Antimicrob Chemother. 2019 Mar 1;74(3):691-698. doi: 10.1093/jac/dky466.

PMID:
30452661
10.

Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient.

Mothobi NZ, Masters J, Marriott DJ.

Ther Adv Infect Dis. 2018 Jul 10;5(5):91-95. doi: 10.1177/2049936118785497. eCollection 2018 Sep.

11.

An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy.

Imani S, Buscher H, Day R, Gentili S, Jones GRD, Marriott D, Norris R, Sandaradura I.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2171-2175. doi: 10.1007/s10096-018-3357-9. Epub 2018 Aug 17.

PMID:
30120647
12.

Invasive Candidiasis in the Elderly: Considerations for Drug Therapy.

Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC.

Drugs Aging. 2018 Sep;35(9):781-789. doi: 10.1007/s40266-018-0576-9. Review.

13.

Running exercise mitigates the negative consequences of chronic stress on dorsal hippocampal long-term potentiation in male mice.

Miller RM, Marriott D, Trotter J, Hammond T, Lyman D, Call T, Walker B, Christensen N, Haynie D, Badura Z, Homan M, Edwards JG.

Neurobiol Learn Mem. 2018 Mar;149:28-38. doi: 10.1016/j.nlm.2018.01.008. Epub 2018 Feb 9.

14.

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance.

Biswas C, Chen SC, Halliday C, Martinez E, Rockett RJ, Wang Q, Timms VJ, Dhakal R, Sadsad R, Kennedy KJ, Playford G, Marriott DJ, Slavin MA, Sorrell TC, Sintchenko V.

J Vis Exp. 2017 Dec 28;(130). doi: 10.3791/56714.

PMID:
29364212
15.

Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.

Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I.

J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897. doi: 10.1093/jac/dkx209.

PMID:
29091190
16.

Changing epidemiology of candidaemia in Australia.

Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, Bak N, Heath CH, Kennedy K, Morrissey CO, Sorrell TC, van Hal S, Keighley C, Goeman E, Underwood N, Hajkowicz K, Hofmeyr A, Leung M, Macesic N, Botes J, Blyth C, Cooley L, George CR, Kalukottege P, Kesson A, McMullan B, Baird R, Robson J, Korman TM, Pendle S, Weeks K, Liu E, Cheong E, Chen S; Australian and New Zealand Mycoses Interest Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1103-1108. doi: 10.1093/jac/dkw422. Erratum in: J Antimicrob Chemother. 2017 Apr 1;72 (4):1270.

PMID:
28364558
17.

Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study.

Biswas C, Chen SC, Halliday C, Kennedy K, Playford EG, Marriott DJ, Slavin MA, Sorrell TC, Sintchenko V.

Clin Microbiol Infect. 2017 Sep;23(9):676.e7-676.e10. doi: 10.1016/j.cmi.2017.03.014. Epub 2017 Mar 23.

18.

Changing epidemiology of candidaemia in Australia.

Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, Bak N, Heath CH, Kennedy K, Morrissey CO, Sorrell TC, van Hal S, Keighley C, Goeman E, Underwood N, Hajkowicz K, Hofmeyr A, Leung M, Macesic N, Botes J, Blyth C, Cooley L, George CR, Kalukottege P, Kesson A, McMullan B, Baird R, Robson J, Korman TM, Pendle S, Weeks K, Liu E, Cheong E, Chen S; Australian and New Zealand Mycoses Interest Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1270. doi: 10.1093/jac/dkx047. No abstract available.

PMID:
28204502
19.

Clinical management of Brucella suis infection in dogs and implications for public health.

James DR, Golovsky G, Thornton JM, Goodchild L, Havlicek M, Martin P, Krockenberger MB, Marriott D, Ahuja V, Malik R, Mor SM.

Aust Vet J. 2017 Jan;95(1-2):19-25. doi: 10.1111/avj.12550.

PMID:
28124423
20.

Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field.

Kelly ML, Pinto AN, Suan D, Marriott D, Cooper DA, Pett SL.

Sex Health. 2017 Jun;14(3):286-288. doi: 10.1071/SH16036.

PMID:
28063460
21.

Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.

Playford EG, Lipman J, Jones M, Lau AF, Kabir M, Chen SC, Marriott DJ, Seppelt I, Gottlieb T, Cheung W, Iredell JR, McBryde ES, Sorrell TC.

Clin Infect Dis. 2016 Dec 1;63(11):1463-1469. Epub 2016 Sep 6.

PMID:
27601224
22.

Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.

Halliday CL, Chen SC, Kidd SE, van Hal S, Chapman B, Heath CH, Lee A, Kennedy KJ, Daveson K, Sorrell TC, Morrissey CO, Marriott DJ, Slavin MA.

Int J Antimicrob Agents. 2016 Oct;48(4):453-8. doi: 10.1016/j.ijantimicag.2016.07.005. Epub 2016 Aug 12.

PMID:
27562696
23.

Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting.

Lindsay PJ, Bond SE, Norris R, Marriott DJ, Miyakis S.

Ther Drug Monit. 2016 Dec;38(6):804-807.

PMID:
27548694
24.

Detection of Dientamoeba fragilis in animal faeces using species specific real time PCR assay.

Chan D, Barratt J, Roberts T, Phillips O, Šlapeta J, Ryan U, Marriott D, Harkness J, Ellis J, Stark D.

Vet Parasitol. 2016 Aug 30;227:42-7. doi: 10.1016/j.vetpar.2016.07.025. Epub 2016 Jul 20.

PMID:
27523936
25.

Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.

Jensen TO, Darley DR, Goeman EE, Shaw K, Marriott DJ, Glanville AR.

Transpl Infect Dis. 2016 Oct;18(5):782-784. doi: 10.1111/tid.12580. Epub 2016 Sep 7.

PMID:
27459235
26.

Angiostrongylus cantonensis: a review of its distribution, molecular biology and clinical significance as a human pathogen.

Barratt J, Chan D, Sandaradura I, Malik R, Spielman D, Lee R, Marriott D, Harkness J, Ellis J, Stark D.

Parasitology. 2016 Aug;143(9):1087-118. doi: 10.1017/S0031182016000652. Epub 2016 May 26. Review.

PMID:
27225800
27.

The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.

Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, Billaud EM, Chambers D, Danziger-Isakov L, Fedson S, Gould K, Gregson A, Grossi P, Hadjiliadis D, Hopkins P, Luong ML, Marriott DJE, Monforte V, Muñoz P, Pasqualotto AC, Roman A, Silveira FP, Teuteberg J, Weigt S, Zaas AK, Zuckerman A, Morrissey O.

J Heart Lung Transplant. 2016 Mar;35(3):261-282. doi: 10.1016/j.healun.2016.01.007. Epub 2016 Jan 19. No abstract available.

PMID:
26970469
28.

Mucormycosis in Australia: contemporary epidemiology and outcomes.

Kennedy KJ, Daveson K, Slavin MA, van Hal SJ, Sorrell TC, Lee A, Marriott DJ, Chapman B, Halliday CL, Hajkowicz K, Athan E, Bak N, Cheong E, Heath CH, Morrissey CO, Kidd S, Beresford R, Blyth C, Korman TM, Robinson JO, Meyer W, Chen SC; Australia and New Zealand Mycoses Interest Group of the Australasian Society for Infectious Diseases.

Clin Microbiol Infect. 2016 Sep;22(9):775-781. doi: 10.1016/j.cmi.2016.01.005. Epub 2016 Jan 20.

29.

Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.

Lee FJ, Marriott D, Bloch M, Richardson R, Mackenzie N, Carr A.

J Antimicrob Chemother. 2016 Apr;71(4):1127-9. doi: 10.1093/jac/dkv436. Epub 2015 Dec 18. No abstract available.

PMID:
26682962
30.

The Prevalence of Angiostrongylus cantonensis/mackerrasae Complex in Molluscs from the Sydney Region.

Chan D, Barratt J, Roberts T, Lee R, Shea M, Marriott D, Harkness J, Malik R, Jones M, Aghazadeh M, Ellis J, Stark D.

PLoS One. 2015 May 22;10(5):e0128128. doi: 10.1371/journal.pone.0128128. eCollection 2015.

31.

Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.

Mubarak N, Sandaradura I, Isaia L, O'Sullivan M, Zhou F, Marriott D, Iredell JR, Harkness J, Andresen D.

J Antimicrob Chemother. 2015 Aug;70(8):2413-4. doi: 10.1093/jac/dkv124. Epub 2015 May 14. No abstract available.

PMID:
25977400
32.

Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency.

Burrows FS, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR.

J Heart Lung Transplant. 2015 Jul;34(7):958-62. doi: 10.1016/j.healun.2015.01.009. Epub 2015 Jan 16.

PMID:
25753833
33.

Molecular epidemiology of imported cases of leishmaniasis in Australia from 2008 to 2014.

Roberts T, Barratt J, Sandaradura I, Lee R, Harkness J, Marriott D, Ellis J, Stark D.

PLoS One. 2015 Mar 3;10(3):e0119212. doi: 10.1371/journal.pone.0119212. eCollection 2015.

34.

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality.

Slavin M, van Hal S, Sorrell TC, Lee A, Marriott DJ, Daveson K, Kennedy K, Hajkowicz K, Halliday C, Athan E, Bak N, Cheong E, Heath CH, Orla Morrissey C, Kidd S, Beresford R, Blyth C, Korman TM, Owen Robinson J, Meyer W, Chen SC; Australia and New Zealand Mycoses Interest Group.

Clin Microbiol Infect. 2015 May;21(5):490.e1-10. doi: 10.1016/j.cmi.2014.12.021. Epub 2015 Jan 14.

35.

Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol.

Lau AF, Kabir M, Chen SC, Playford EG, Marriott DJ, Jones M, Lipman J, McBryde E, Gottlieb T, Cheung W, Seppelt I, Iredell J, Sorrell TC.

J Clin Microbiol. 2015 Apr;53(4):1324-30. doi: 10.1128/JCM.03239-14. Epub 2015 Feb 11.

36.

Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.

Chau MM, Kong DC, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, Wilkes J, Cooper CM, Roberts JA, Marriott DJ, Worth LJ.

Intern Med J. 2014 Dec;44(12b):1364-88. doi: 10.1111/imj.12600. Review.

PMID:
25482746
37.

Miliary pulmonary cryptococcosis.

Kelly S, Marriott D.

Med Mycol Case Rep. 2014 Aug 11;6:22-4. doi: 10.1016/j.mmcr.2014.08.004. eCollection 2014 Oct.

38.

Activity of benzimidazoles against Dientamoeba fragilis (Trichomonadida, Monocercomonadidae) in vitro and correlation of beta-tubulin sequences as an indicator of resistance.

Stark D, Barratt JL, Roberts T, Marriott D, Harkness JT, Ellis J.

Parasite. 2014;21:41. doi: 10.1051/parasite/2014043. Epub 2014 Aug 25.

39.

Description of Dientamoeba fragilis cyst and precystic forms from human samples.

Stark D, Garcia LS, Barratt JL, Phillips O, Roberts T, Marriott D, Harkness J, Ellis JT.

J Clin Microbiol. 2014 Jul;52(7):2680-3. doi: 10.1128/JCM.00813-14. Epub 2014 May 7.

40.

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

van Hal SJ, Chen SC, Sorrell TC, Ellis DH, Slavin M, Marriott DM.

J Antimicrob Chemother. 2014 Aug;69(8):2210-4. doi: 10.1093/jac/dku124. Epub 2014 Apr 30.

PMID:
24788656
41.

Anncaliia algerae microsporidial myositis.

Watts MR, Chan RC, Cheong EY, Brammah S, Clezy KR, Tong C, Marriott D, Webb CE, Chacko B, Tobias V, Outhred AC, Field AS, Prowse MV, Bertouch JV, Stark D, Reddel SW.

Emerg Infect Dis. 2014 Feb;20(2):185-91. doi: 10.3201/eid2002.131126.

42.

Evaluation of the EasyScreen™ enteric parasite detection kit for the detection of Blastocystis spp., Cryptosporidium spp., Dientamoeba fragilis, Entamoeba complex, and Giardia intestinalis from clinical stool samples.

Stark D, Roberts T, Ellis JT, Marriott D, Harkness J.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):149-52. doi: 10.1016/j.diagmicrobio.2013.10.013. Epub 2013 Oct 23.

PMID:
24286625
43.

Treatment failure in patients with chronic Blastocystis infection.

Roberts T, Ellis J, Harkness J, Marriott D, Stark D.

J Med Microbiol. 2014 Feb;63(Pt 2):252-7. doi: 10.1099/jmm.0.065508-0. Epub 2013 Nov 15.

PMID:
24243286
44.

Effect of breed on fatty acid composition and lipogenic enzyme abundance in the subcutaneous adipose tissue of pigs.

Marriott DT, Chevillon P, Spencer-Phillips PT, Doran O.

J Food Sci. 2013 Aug;78(8):C1130-5. doi: 10.1111/1750-3841.12191.

PMID:
23957397
45.

Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem?

Chapman JR, Marriott DJ, Chen SC, MacDonald PS.

Kidney Int. 2013 Aug;84(2):240-3. doi: 10.1038/ki.2013.212. Epub 2013 Jun 5.

46.

Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii.

Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie BJ, Hajkowicz K, Heath CH, Kidd S, McBride WJ, Meyer W, Murray R, Playford EG, Sorrell TC; Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study.

Clin Infect Dis. 2013 Aug;57(4):543-51. doi: 10.1093/cid/cit341. Epub 2013 May 22.

PMID:
23697747
47.

Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).

Neoh CF, Liew D, Slavin MA, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.

Mycoses. 2013 Sep;56(5):532-42. doi: 10.1111/myc.12071. Epub 2013 Mar 18.

PMID:
23496163
48.

Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.

Neoh CF, Liew D, Slavin MA, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.

Intern Med J. 2013 Jun;43(6):668-77. doi: 10.1111/imj.12110.

PMID:
23461421
49.

Comparing dose prediction software used to manage gentamicin dosing.

Wong C, Kumar SS, Graham GG, Begg EJ, Chin PK, Brett J, Ray JE, Marriott DJ, Williams KM, Day RO.

Intern Med J. 2013 May;43(5):519-25. doi: 10.1111/imj.12067.

PMID:
23279297
50.

Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults.

Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):525-33.

PMID:
23274936

Supplemental Content

Loading ...
Support Center